Increasing Protein Intake May Help Prevent Muscle Loss in Patients Using Anti-Obesity Medication

Recent research presented at ENDO 2025, the annual meeting of the Endocrine Society, highlights the potential benefits of higher dietary protein for individuals taking the weight-loss drug semaglutide. This medication, part of the GLP-1 receptor agonists, is effective in promoting weight reduction but is associated with muscle loss, which can adversely impact metabolism, bone health, and overall well-being.

A study involving 40 adults with obesity over three months found that those on semaglutide lost more weight compared to participants in a diet and lifestyle program called Healthy Habits for Life. While the percentage of lean mass lost was similar between both groups, factors such as older age, female gender, and lower protein consumption were linked to greater muscle loss in the semaglutide group. Importantly, increased muscle loss was associated with less improvement in blood sugar control, as measured by HbA1c levels.

The findings suggest that older adults and women might be more vulnerable to muscle loss during semaglutide treatment, but adequate protein intake could serve as a protective factor. Maintaining muscle mass is crucial since it supports proper blood sugar regulation and bone strength, helping to prevent frailty and insulin resistance in people undergoing weight-loss therapy.

Experts emphasize the need for further research to optimize fat loss strategies that preserve muscle during the use of GLP-1 medications. Their goal is to enhance the effectiveness of obesity treatments while minimizing unwanted side effects like muscle wasting.

Source: https://medicalxpress.com/news/2025-07-consuming-protein-patients-anti-obesity.html